Hospira’s Device Shortage Response Draws FDA Warning Letter For Product Release
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA isn’t convinced by Hospira’s explanation for why it released non-GMP compliant product from its Rocky Mount plant, which also manufactures sterile injectables.